Showing posts with label Empagliflozin. Show all posts
Showing posts with label Empagliflozin. Show all posts
Monday, February 9, 2026

Intranasal Insulin, Empagliflozin Have Promising Effects on Cognition

›
In continuation of my update Empagliflozan Intranasal insulin (INI) and empagliflozin are safe and have promising effects on cognition, acco...
Wednesday, August 9, 2017

New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

›
The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular d...
Monday, January 23, 2017

Empagliflozin offers long-term renal protection in Type 2 diabetes

›
The sodium-glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of t...
Friday, December 16, 2016

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

›
In continuation of my update on  Empagliflozin Empagliflozin (trade name: Jardiance) has been approved since May 2014 for adults...
Friday, December 25, 2015

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

›
In continuation of my update on  Empagliflozin For the first time, research shows that a type 2 diabetes drug significantly reduc...
Monday, October 22, 2012

Empagliflozin Lowers Blood Pressure | News | Drug Discovery and Development Magazine

›
We know that, Empagliflozin (see structure) is a SGLT2 inhibitor which is being investigated in clinical trials for the oral treatment ...